AntineoplasticsLack of efficacy, and fatigue and thrombocytopenia following off-label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2022年 / 1919卷 / 1期

关键词：

D O I：

10.1007/s40278-022-21013-5

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：71 / 71

相关论文

共 50 条

[41] TocilizumabLack of efficacy following off-label use: case report
[J]. Reactions Weekly, 2022, 1887 (1) : 643 - 643
[42] ApixabanLack of efficacy following off-label use: case report
[J]. Reactions Weekly, 2022, 1935 (1) : 89 - 89
[43] AntineoplasticsLack of efficacy followed by off-label use: 2 case reports
[J]. Reactions Weekly, 2023, 1956 (1) : 64 - 64
[44] TeriparatideHeadache, fatigue and myalgia following off-label use: case report
[J]. Reactions Weekly, 2021, 1857 (1) : 320 - 320
[45] Camrelizumab/rivoceranibHypertension, leucopenia and thrombocytopenia following off-label use: case report
[J]. Reactions Weekly, 2022, 1895 (1) : 111 - 111
[46] CobimetinibExtremity swelling, thrombocytopenia and diarrhoea following off-label use: case report
[J]. Reactions Weekly, 2022, 1912 (1) : 158 - 158
[47] Multiple drugsLeucopenia and thrombocytopenia following off-label use and ineffectiveness: case report
[J]. Reactions Weekly, 2023, 1959 (1) : 468 - 468
[48] Cetuximab/cisplatin/gemcitabineLeukocytopenia and thrombocytopenia following off-label use: case report
[J]. Reactions Weekly, 2022, 1917 (1) : 168 - 168
[49] Multiple drugsVancomycin resistance and thrombocytopenia following off-label use: case report
[J]. Reactions Weekly, 2023, 1958 (1) : 389 - 389
[50] Dexamethasone/tocilizumabLack of efficacy following off-label use: case report
[J]. Reactions Weekly, 2023, 1968 (1) : 122 - 122

← 1 2 3 4 5 →